Targeting Cancer Drug Resistance with Kairos Pharma’s CEO Dr. John Yu

In this episode, Ayesha spoke with John Yu, MD, CEO of Kairos Pharma, a company advancing therapies to overcome challenges in cancer drug resistance and immune suppression.

Kairos is developing therapeutics that reverse cancer drug resistance in cancers such as prostate and lung cancer. The company’s lead candidate, ENV105, is an antibody targeting CD105, which is implicated in cancer cell resistance to various treatments. By inhibiting CD105, ENV105 seeks to restore the effectiveness of standard therapies across multiple cancer types.

Dr. Yu is also Professor and Clinical Chief of Neurosurgery, Director of the Brain Tumor Center at Cedars Sinai Medical Center.

He has developed numerous immunotherapies and nanotechnologies from his National Institutes of Health (NIH) funded laboratory. This includes eight new investigational drugs with the US Food and Drug Administration. Dr. Yu has also led numerous clinical trials.

Dr. Yu served in leadership roles at several biotechs, including ImmunoCellular Therapeutics and most recently served as CEO and Chairman of AcTcell and Director of Enviro Therapeutics.

Dr. Yu has an MD from Harvard Medical School and MIT, and completed an Immunology Fellowship at the Institut Pasteur, Paris.

Tune into the episode, to hear more about the work Dr. Yu is leading at Kairos Pharma to address cancer drug resistance.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured